Sigrid Therapeutics AB

[Not Yet Scheduled]
Sigrid Therapeutics AB (Sigrid) is a clinical-stage technology company with a vision to prevent disease and improve people’s health globally.
The Company’s first product SiPore15 lowers blood sugar in people at risk of developing type 2 diabetes, prediabetes, and people suffering from type 2 diabetes.
The prevalence of prediabetes and type 2 diabetes is increasing worldwide, and it is projected that over 1 billion people will suffer from these conditions by 2040.
There are no approved therapies for the management of prediabetes and drugs for type 2 diabetes have serious side effects. This poses a high unmet clinical need and a substantial commercial opportunity.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Sweden
Year Founded:
2014
Main Therapeutic Focus:
Lead Product in Development:
SiPore15
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CTO
Sigrid Therapeutics